In collaboration with University of Utrecht researchers, an analysis of assessed indications in 4 Beneluxa countries was carried out: Austria, Belgium, Ireland and the Netherlands. For BE, IE and NL, the conclusions on added benefit and the reasons for any differences in...
The Beneluxa Initiative aims to ensure sustainable access
to innovative medicine at affordable cost for our patients.
Joint publication analysing the feasibility of joint HTA between Beneluxa countries
Beneluxa General Assembly 28 June 2023
At the end of June 2023, the Beneluxa Initiative organised its biggest General Assembly meeting yet. Over 40 participants joined us at the lively city centre of Dublin, Ireland. The overarching theme of the meeting was Collaboration: Collaboration on different levels and in...
Beneluxa statement at EPSCO Council in June 2023: Applying a needs-driven approach to pharmaceutical innovation
The topic of “a needs-driven approach for pharmaceutical innovation” was brought on the Agenda of the EPSCO Council on June 13th 2023 at the request of the members of the Beneluxa initiative (Belgium, the Netherlands, Luxembourg, Austria and Ireland). In a patient-centred...